Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TV005 Vaccine Protection Against DENV-3 Challenge
NCT02873260Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2016
- Primary completion
- Nov 2017
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TV005 in dengue fever, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Adverse Events at Day 360. Started Aug 2016; status: completed.
02
Drugs
TV005
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT02873260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02873260.